Blindness News and Research

RSS

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Black fly's blood-sucking tactics may be used for medical advancement

Black flies drink blood and spread disease such as river blindness-creating misery with their presence. A University of Georgia study, however, proves that the pesky insects can be useful.

9 Apr 2012

New text messaging program to manage diabetes

D.C. Chartered Health Plan, Inc., the oldest Medicaid managed care organization in the District of Columbia, is launching a new text messaging program for 50 of its members to help them better manage diabetes, which requires regular care to avoid costly complications.

9 Apr 2012

A step closer to correcting unhealthy gene mutations with diet

Scientists have moved a step closer to correcting some unhealthy gene mutations with diet, according to a new research report appearing in the April 2012 issue of the journal GENETICS.

9 Apr 2012

Inflammasome involved in regulating Age-Related Macular Degeneration

Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration.

9 Apr 2012

Researchers discover two molecules that control liver glucose production

In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose---- the simple sugar that is the source of energy in human cells and the central player in diabetes.

9 Apr 2012

Innovative tool for tracking movement of infectious diseases

It may seem like a game of tag, but it's an innovative tool for teaching the fundamentals of epidemiology, the science of how infectious diseases move through a population.

7 Apr 2012

Public not as willing to pay for effective mental illness treatments

An analysis of a nationally representative sample of 710 adult respondents reveals that the public is less willing to pay to avoid mental illnesses compared to paying for treatment of medical conditions.

6 Apr 2012

SelectHealth announces 2012 Select 25 award recipients

SelectHealth is pleased to announce the recipients of the 2012 Select 25 award. The nonprofit health insurance carrier will give $2,500 to each of the 25 winners to assist them in their efforts to improve health and wellness, or to serve populations with special needs.

6 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Recycled glasses costs twice as much as ready-made glasses

You might feel good sending your old reading glasses to a developing country. But a recent international study, led by the International Centre for Eyecare Education (ICEE), a collaborating partner in the Vision CRC, in Sydney, suggests it is far better to give $10 for an eye examination and a new pair of glasses if you want to help someone in desperate need, and it is far better for building capacity in these communities.

5 Apr 2012

Stress-induced tolerance can prevent glaucoma

Working in mice, scientists at Washington University School of Medicine in St. Louis have devised a treatment that prevents the optic nerve injury that occurs in glaucoma, a neurodegenerative disease that is a leading cause of blindness.

4 Apr 2012

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team.

3 Apr 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Bariatric surgery may eliminate need for diabetes medication

Diabetes has become an epidemic in the United States, with the number of cases tripling over the last three decades. Most of those cases are Type 2 diabetes, which is linked to obesity and can lead to serious medical issues that range from heart disease to renal failure, blindness, and more.

29 Mar 2012

IU biologist to genetically modify variants of chlamydia

An Indiana University biologist has been awarded over $2.3 million from the National Institutes of Health to genetically modify variants of the human pathogen chlamydia in hopes of finding a vaccine for the most commonly reported bacterial infectious disease in the United States.

27 Mar 2012

Study provides important clue in type 1 diabetes

In type 1 diabetes (T1D), pancreatic beta cells die from a misguided autoimmune attack, but how and why that happens is still unclear. Now, JDRF-funded scientists from the Indiana University School of Medicine have found that a specific type of cellular stress takes place in pancreatic beta cells before the onset of T1D, and that this stress response in the beta cell may in fact help ignite the autoimmune attack.

23 Mar 2012

CNN examines nodding disease among children in Northern Uganda

CNN examines nodding disease, a seizure disorder that has affected at least 3,000 children in Northern Uganda, as well as children in Liberia, Sudan, and Tanzania.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

Single dose of X-ray radiation can prevent glaucoma

Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from glaucoma.

20 Mar 2012